Skip to main content

Table 2 Clinicopathological characteristics, treatments after local recurrence and outcome of patients with local wall recurrence

From: Risk factors of local recurrence following implant-based breast reconstruction in breast cancer patients

Patient No 1 2 3 4 5 6 7 8 9 10 11 12
Clinical characteristics
Primary
 Age 51 45 40 37 39 37 48 41 46 40 47 45
 Tumor size Is Is Is 1 1 1 1 2 2 2 2 2
 Nodal status 0 0 0 0 0 0 0 0 1 1 1 1
 Stage 0 0 0 I A I A I A I A II A II B II B II B II B
 MRI findings Segmental Segmental Segmental Segmental Segmental Segmental Segmental Segmental Isolated mass Segmental Segmental Segmental
 Operation NSM TM TM TM TM TM TM TM TM TM TM TM
 Adjuvant therapy HT HT HT CT, HT CT + Trastuzumab oral CT, HT CT, HT CT, HT
 Opportunity to detect recurrent lesions Nipple erosion Palpation Imaging inspection Palpation Palpation Palpation Palpation Palpation Palpation Imaging inspection Palpation Palpation
Recurrence
 Local recurrence site             
 Needle biopsy tract            +   +   + 
 Skin just above primary lesion           +   +    
 Subcutaneous tumor around primary lesion    +   +   +   +   +   +   +      
 Other Residual nipple            
 Other recurrent site Bone, Lung
Pathological characteristics (Primary/Recurrence)
Histology DCIS/Paget's disease with invasion DCIS/IDC DCIS/IDC Mucinous/Mucinous IDC + ILC/IDC IDC/lymph node metastasis IDC/lymph node metastasis Mucinous/Mucinous IDC/IDC IDC/IDC IDC/IDC IDC/IDC
Hormone receptor −/−  + / +   + / +   + / +   + / +  −/−  + / +   + / +   + / +   + / +   + / +   + / + 
HER2  + / +  −/− −/− −/− −/−  + / +  −/ +  −/−  + / +  −/− −/− −/−
Ki-67  < 15%/ > 80%  < 15%/ < 15%  < 30%/ < 15% < 15% < 15% <  < 15%  < 15%/ < 15%  < 15%/ < 15%  < 80%/ < 50%  < 30%/ < 15% < 15% < 15%  < 30%/ < 15%  < 80%/ < 50%  < 15%/ < 15%  < 15%/ < 15%  > 15%/ < 50% 30,305,050%
Subtype HER/HER LA/LA LA/LA LA/LA LA/LA HER/HER LB/LH LB/LA HER/HER LA/LA LA/LA LB/LB
Pathological characteristics ( Before/After recurrence)
Nuclear grade* High/3 Low/1 Intermediate/1 11/1 1/1 1/1 3/3 3/3 2/1 3/3 1/1 1/1 2/3
Lymphatic vessel invasion −/ +  −/− −/−  ±   + / +   + / +   + / +   ±   + / +   + / +   + / +   + / + 
Vertical margin (at the time of reconstruction) Not evaluated  < 2 mm: DCIS  < 2 mm: DCIS  < 2 mm: Invasive  < 2 mm: DCIS  + : DCIS  < 2 mm: DCIS  < 2 mm: DCIS  < 2 mm: Invasive Not evaluated  < 2 mm: Invasive
Tissues from recurrence site Residual nipple lactiferous duct Residual mammary tissue Residual mammary tissue Subcutaneous fat Skin ~ subcutaneous fat Lymph node Lymph node Subcutaneous fat Skin Skin ~ subcutaneous fat Skin ~ subcutaneous fat Skin ~ subcutaneous fat
Treatment after recurrence
Operation  +   +   +   +   +   +   +   +   +   +   +   + 
Radiation  +   +   +   +   +   +   +   +   + 
Pharmacological treatment HT, CT + Trastuzumab HT HT HT HT CT + Trastuzumab HT HT T-DM1 HT HT CT, HT
Outcome
Local recurrence free survival (M) 155 42 122 19 31 12 39 12 9 24 19 71
Overall survival (M) 184 61 127 97 75 57 57 57 61 71 55 86
Survival  +   +   +   +   +   +   +   +   +   +   +   + 
  1. Segmental, segmental lesion; NSM, nipple-sparing mastectomy; TM, total mastectomy; HT, hormonal therapy; CT, chemotherapy; Mucinous, mucinous carcinoma; LA, luminal A-like; LB, luminal B-like/HER2 positive; LH, luminal B-like/HER2 negative; HER, HER2 positive; T-DM1, trastuzumab emtansine; *DCIS: low/intermediate/high grade